American Association for Cancer Research
Browse

Supplementary Fig. S3 from UA62784, a novel inhibitor of centromere protein E kinesin-like protein

Download (66.72 kB)
journal contribution
posted on 2023-03-31, 23:02 authored by Meredith C. Henderson, Yeng-Jeng Y. Shaw, Hong Wang, Haiyong Han, Laurence H. Hurley, Gary Flynn, Robert T. Dorr, Daniel D. Von Hoff
Supplementary Fig. S3 from UA62784, a novel inhibitor of centromere protein E kinesin-like protein

History

ARTICLE ABSTRACT

Pancreatic carcinoma is the fourth leading cause of death from cancer. Novel targets and therapeutic options are needed to aid in the treatment of pancreatic cancer. The compound UA62784 is a novel fluorenone with inhibitory activity against the centromere protein E (CENP-E) kinesin-like protein. UA62784 was isolated due to its selectivity in isogenic pancreatic carcinoma cell lines with a deletion of the DPC4 gene. UA62784 causes mitotic arrest by inhibiting chromosome congression at the metaphase plate likely through inhibition of the microtubule-associated ATPase activity of CENP-E. Furthermore, CENP-E binding to kinetochores during mitosis is not affected by UA62784, suggesting that the target lies within the motor domain of CENP-E. UA62784 is a novel specific inhibitor of CENP-E and its activity suggests a potential role for antimitotic drugs in treating pancreatic carcinomas. [Mol Cancer Ther 2009;8(1):36–44]

Usage metrics

    Molecular Cancer Therapeutics

    Licence

    Exports

    RefWorks
    BibTeX
    Ref. manager
    Endnote
    DataCite
    NLM
    DC